Relay Therapeutics Inc (RLAY)

NASDAQ:RLAY

RLAY

Relay Therapeutics

RESEARCH TOOLSreports

Want to see RLAY full AI Analyst Report?

Relay Therapeutics (RLAY) Stock Forecast & Price Target

580 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

RLAY Analyst Ratings

Strong Buy

9 Buy

1 Hold

0 Sell

Based on 10 analysts giving stock ratings to

Relay

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

RLAY Stock 12 Month Forecast

Average Price Target

$20.78

▲(23.97% Upside)

Based on 10 Wall Street analysts offering 12 month price targets for Relay Therapeutics in the last 3 months. The average price target is $20.78 with a high forecast of $25.00 and a low forecast of $18.00. The average price target represents a 23.97% change from the last price of $16.76.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","8":"$8","14":"$14","20":"$20","26":"$26"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20.77777777777778,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$20.78</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$18.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,8,14,20,26],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.72,13.664615384615384,14.60923076923077,15.553846153846154,16.498461538461537,17.443076923076923,18.38769230769231,19.332307692307694,20.276923076923076,21.22153846153846,22.166153846153847,23.11076923076923,24.055384615384614,{"y":25,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.72,13.33982905982906,13.95965811965812,14.579487179487181,15.19931623931624,15.819145299145301,16.43897435897436,17.05880341880342,17.67863247863248,18.298461538461538,18.9182905982906,19.53811965811966,20.15794871794872,{"y":20.77777777777778,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.72,13.126153846153846,13.532307692307693,13.938461538461539,14.344615384615384,14.750769230769231,15.156923076923077,15.563076923076924,15.96923076923077,16.375384615384615,16.78153846153846,17.18769230769231,17.593846153846155,{"y":18,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.29,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.18,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.52,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.36,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.66,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.32,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.14,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.4,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.46,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.15,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.79,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.77,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.72,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$25.00

Average Price Target$20.78

Lowest Price Target$18.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Salveen Richter

Goldman Sachs

$13→$22

Buy

31.26%

Upside

Reiterated

05/04/26

Analysts Offer Insights on Healthcare Companies: Relay Therapeutics (NASDAQ: RLAY), Cigna (NYSE: CI) and Sotera Health (NASDAQ: SHC)

Robert Burns

H.C. Wainwright

$19→$25

Buy

49.16%

Upside

Reiterated

04/29/26

Relay Therapeutics price target raised to $25 from $19 at H.C. WainwrightRelay Therapeutics price target raised to $25 from $19 at H.C. Wainwright

Etzer Darout

Barclays

$21

Buy

25.30%

Upside

Reiterated

04/28/26

Barclays Reaffirms Their Buy Rating on Relay Therapeutics (RLAY)

Eva Fortea Verdejo

Wells Fargo

$21

Buy

25.30%

Upside

Reiterated

04/28/26

Relay Therapeutics price target raised to $21 from $17 at Wells FargoRelay Therapeutics price target raised to $21 from $17 at Wells Fargo

Silvan Tuerkcan

Citizens JMP

$17→$19

Buy

13.37%

Upside

Reiterated

04/28/26

Relay Therapeutics price target raised to $19 from $17 at CitizensRelay Therapeutics price target raised to $19 from $17 at Citizens

Matthew Biegler

Oppenheimer

$14→$18

Buy

7.40%

Upside

Reiterated

04/28/26

Analysts Offer Insights on Healthcare Companies: Fulcrum Therapeutics (NASDAQ: FULC) and Relay Therapeutics (NASDAQ: RLAY)

Boris Peaker

JonesTrading

$18

Hold

7.40%

Upside

Reiterated

04/27/26

Analysts Offer Insights on Healthcare Companies: Cormedix (NASDAQ: CRMD) and Relay Therapeutics (NASDAQ: RLAY)

Chi Meng Fong

Bank of America Securities

$21

Buy

25.30%

Upside

Reiterated

04/27/26

Analyst Reiterates Buy on Relay Therapeutics, Citing Promising Zovega mBC Data, Favorable Safety Profile, and Phase 3 First-Line Breast Cancer Upside

Bradley Canino

Guggenheim

$15→$22

Buy

31.26%

Upside

Reiterated

03/12/26

Guggenheim Sticks to Its Buy Rating for Relay Therapeutics (RLAY)

Yaron Werber

TD Cowen

―

Buy

―

Reiterated

02/26/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Andrew Berens

Leerink Partners

$12

Buy

-28.40%

Downside

Reiterated

08/12/25

Relay Therapeutics (RLAY) Receives a Buy from Leerink Partners

Sean McCutcheon

Raymond James

$29→$19

Buy

13.37%

Upside

Reiterated

08/08/25

Relay Therapeutics price target lowered to $19 from $29 at Raymond JamesRelay Therapeutics price target lowered to $19 from $29 at Raymond James

Eric Joseph

J.P. Morgan

$21→$11

Buy

-34.37%

Downside

Reiterated

05/13/25

Relay Therapeutics (RLAY) PT Lowered to $11 at JPMorganJPMorgan analyst Eric Joseph lowered the price target on Relay Therapeutics (NASDAQ: RLAY) to $11.00 (from $21.00) while maintaining a Overweight rating.

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Salveen Richter

Goldman Sachs

$13→$22

Buy

31.26%

Upside

Reiterated

05/04/26

Analysts Offer Insights on Healthcare Companies: Relay Therapeutics (NASDAQ: RLAY), Cigna (NYSE: CI) and Sotera Health (NASDAQ: SHC)

Robert Burns

H.C. Wainwright

$19→$25

Buy

49.16%

Upside

Reiterated

04/29/26

Relay Therapeutics price target raised to $25 from $19 at H.C. WainwrightRelay Therapeutics price target raised to $25 from $19 at H.C. Wainwright

Etzer Darout

Barclays

$21

Buy

25.30%

Upside

Reiterated

04/28/26

Barclays Reaffirms Their Buy Rating on Relay Therapeutics (RLAY)

Eva Fortea Verdejo

Wells Fargo

$21

Buy

25.30%

Upside

Reiterated

04/28/26

Relay Therapeutics price target raised to $21 from $17 at Wells FargoRelay Therapeutics price target raised to $21 from $17 at Wells Fargo

Silvan Tuerkcan

Citizens JMP

$17→$19

Buy

13.37%

Upside

Reiterated

04/28/26

Relay Therapeutics price target raised to $19 from $17 at CitizensRelay Therapeutics price target raised to $19 from $17 at Citizens

Matthew Biegler

Oppenheimer

$14→$18

Buy

7.40%

Upside

Reiterated

04/28/26

Analysts Offer Insights on Healthcare Companies: Fulcrum Therapeutics (NASDAQ: FULC) and Relay Therapeutics (NASDAQ: RLAY)

Boris Peaker

JonesTrading

$18

Hold

7.40%

Upside

Reiterated

04/27/26

Analysts Offer Insights on Healthcare Companies: Cormedix (NASDAQ: CRMD) and Relay Therapeutics (NASDAQ: RLAY)

Chi Meng Fong

Bank of America Securities

$21

Buy

25.30%

Upside

Reiterated

04/27/26

Analyst Reiterates Buy on Relay Therapeutics, Citing Promising Zovega mBC Data, Favorable Safety Profile, and Phase 3 First-Line Breast Cancer Upside

Bradley Canino

Guggenheim

$15→$22

Buy

31.26%

Upside

Reiterated

03/12/26

Guggenheim Sticks to Its Buy Rating for Relay Therapeutics (RLAY)

Yaron Werber

TD Cowen

―

Buy

―

Reiterated

02/26/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Andrew Berens

Leerink Partners

$12

Buy

-28.40%

Downside

Reiterated

08/12/25

Relay Therapeutics (RLAY) Receives a Buy from Leerink Partners

Sean McCutcheon

Raymond James

$29→$19

Buy

13.37%

Upside

Reiterated

08/08/25

Relay Therapeutics price target lowered to $19 from $29 at Raymond JamesRelay Therapeutics price target lowered to $19 from $29 at Raymond James

Eric Joseph

J.P. Morgan

$21→$11

Buy

-34.37%

Downside

Reiterated

05/13/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Relay Therapeutics

3 Months

xxx

Success Rate

7/14 ratings generated profit

Average Return

+4.35%

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +4.35% per trade.

1 Year

Andrew BerensLeerink Partners

Success Rate

6/11 ratings generated profit

Average Return

+102.43%

Copying Andrew Berens's trades and holding each position for 1 Year would result in 54.55% of your transactions generating a profit, with an average return of +102.43% per trade.

2 Years

xxx

Success Rate

11/11 ratings generated profit

Average Return

+182.37%

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +182.37% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RLAY Analyst Recommendation Trends

Rating

Jan 26

Feb 26

Mar 26

Apr 26

May 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, RLAY has received 15 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. RLAY average Analyst price target in the past 3 months is 20.78.

Each month's total comprises the sum of three months' worth of ratings.

RLAY Financial Forecast

RLAY Earnings Forecast

Currently, no earnings data available.

RLAY Sales Forecast

Currently, no sales data available.

RLAY Stock Forecast FAQ

What is RLAY’s average 12-month price target, according to analysts?

Based on analyst ratings, Relay Therapeutics Inc’s 12-month average price target is 20.78.

What is RLAY’s upside potential, based on the analysts’ average price target?

Relay Therapeutics Inc has 23.97% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is RLAY a Buy, Sell or Hold?

Relay Therapeutics Inc has a consensus rating of Strong Buy which is based on 9 buy ratings, 1 hold ratings and 0 sell ratings.

What is Relay Therapeutics Inc’s price target?

The average price target for Relay Therapeutics Inc is 20.78. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $25.00 ,the lowest forecast is $18.00. The average price target represents 23.97% Increase from the current price of $16.76.

What do analysts say about Relay Therapeutics Inc?

Relay Therapeutics Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.

How can I buy shares of RLAY?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Relay Therapeutics (RLAY) Stock Forecast & Price Target

RLAY Analyst Ratings

RLAY Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Relay Therapeutics

RLAY Analyst Recommendation Trends

RLAY Financial Forecast

RLAY Earnings Forecast

RLAY Sales Forecast

RLAY Stock Forecast FAQ

Detailed List of Analyst Forecasts